BTIG Maintains Buy on CymaBay Therapeutics, Raises Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Julian Harrison maintains a Buy rating on CymaBay Therapeutics (NASDAQ:CBAY) and raises the price target from $18 to $22.

August 11, 2023 | 4:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CymaBay Therapeutics' price target has been raised from $18 to $22 by BTIG, maintaining a Buy rating.
The news of BTIG analyst Julian Harrison maintaining a Buy rating on CymaBay Therapeutics and raising the price target from $18 to $22 is likely to have a positive impact on the company's stock in the short term. This is because such an upgrade usually signals the analyst's increased confidence in the company's future performance, which can encourage investors to buy the stock, potentially driving up its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100